Trademark: LUTELIS 2324279
Word
LUTELIS
ID
2324279
Trademark Type
Word
Status
Registered: Registered/protected
Application Date
22 December 2022
Registration Date
22 December 2022
Renewal Date
22 December 2032
Owner(s)
Service
WRAYS PTY LTD
Goods and Services:
Class 5:
Pharmaceutical preparations and substances in the nature of hormone replacement therapy [HRT]; pharmaceutical preparations and substances for use in relation to endometrial hyperplasia; pharmaceutical preparations and substances for use in relation to the prevention and treatment of endometrial carcinoma; pharmaceutical preparations and substances for use as an adjunct to oestrogen therapy; pharmaceutical preparations and substances for use in relation to the treatment of progesterone deficiency; pharmaceutical preparations and substances for use in relation to assisting conception and supporting gestation; pharmaceutical preparations and substances for use in relation to pregnancy; pharmaceutical preparations and substances for use in relation to prevention of premature birth; pharmaceutical preparations and substances for use in relation to reproductive health; pharmaceutical preparations and substances for use in relation to conception; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in gynaecology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; none of the aforementioned goods for or in relation to ophthalmic or ophthalmological goods; none of the aforementioned goods being injectable.
Pharmaceutical preparations and substances in the nature of hormone replacement therapy [HRT]; pharmaceutical preparations and substances for use in relation to endometrial hyperplasia; pharmaceutical preparations and substances for use in relation to the prevention and treatment of endometrial carcinoma; pharmaceutical preparations and substances for use as an adjunct to oestrogen therapy; pharmaceutical preparations and substances for use in relation to the treatment of progesterone deficiency; pharmaceutical preparations and substances for use in relation to assisting conception and supporting gestation; pharmaceutical preparations and substances for use in relation to pregnancy; pharmaceutical preparations and substances for use in relation to prevention of premature birth; pharmaceutical preparations and substances for use in relation to reproductive health; pharmaceutical preparations and substances for use in relation to conception; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in gynaecology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; none of the aforementioned goods for or in relation to ophthalmic or ophthalmological goods; none of the aforementioned goods being injectable.